Terms: = Breast cancer AND BCL3, P20749, 602, ENSG00000069399, D19S37, BCL4 AND Clinical Outcome
4 results:
1. Magnetic resonance (MR) features in triple negative breast cancer (TNBC) vs receptor positive cancer (nTNBC).
Angelini G; Marini C; Iacconi C; Mazzotta D; Moretti M; Picano E; Morganti R
Clin Imaging; 2018; 49():12-16. PubMed ID: 29120811
[TBL] [Abstract] [Full Text] [Related]
2. Distinctive role of SIRT1 expression on tumor invasion and metastasis in breast cancer by molecular subtype.
Chung YR; Kim H; Park SY; Park IA; Jang JJ; Choe JY; Jung YY; Im SA; Moon HG; Lee KH; Suh KJ; Kim TY; Noh DY; Han W; Ryu HS
Hum Pathol; 2015 Jul; 46(7):1027-35. PubMed ID: 26004371
[TBL] [Abstract] [Full Text] [Related]
3. MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells.
Zhao Y; Li Y; Lou G; Zhao L; Xu Z; Zhang Y; He F
PLoS One; 2012; 7(6):e39102. PubMed ID: 22723937
[TBL] [Abstract] [Full Text] [Related]
4. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.
Joerger M; Huitema AD; Richel DJ; Dittrich C; Pavlidis N; Briasoulis E; Vermorken JB; Strocchi E; Martoni A; Sorio R; Sleeboom HP; Izquierdo MA; Jodrell DI; Féty R; de Bruijn E; Hempel G; Karlsson M; Tranchand B; Schrijvers AH; Twelves C; Beijnen JH; Schellens JH;
Clin Pharmacokinet; 2007; 46(12):1051-68. PubMed ID: 18027989
[TBL] [Abstract] [Full Text] [Related]
